Compare Incyte Corporation (INCY) vs Navan Inc. Class A Common Stock (NAVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Navan Inc. Class A Common Stock — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.85B), while Navan Inc. Class A Common Stock trades at $23.16 (market cap $6.01B). The key difference: Incyte Corporation is far larger — about 3.8× Navan Inc. Class A Common Stock's market cap, and Navan Inc. Class A Common Stock is more actively traded (2,990,425 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Navan Inc. Class A Common Stock for 0 Days on average.
| INCY | NAVN | |
|---|---|---|
Market Cap | $22.85B | $6.01B |
Volume | 1,927,029 | 2,990,425 |
Sector | Health | Technology |
52-Week High | $129.93 | $30.58 |
52-Week Low | $83.80 | $8.51 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.35B | $5.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →
